Business
Board Change
Board Change.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 4848I hVIVO plc 20 June 2017 \n\nFor immediate release 7.00am: 20 June 2017\n \nHVIVO PLC\n(\"hVIVO\" or the \"Company\")\n \nBoard Change\n \nhVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, is pleased to announce the appointment of Dr Trevor Phillips as a Non-Executive Director, with immediate effect.\n \nTrevor has over thirty years' of experience within the pharmaceutical industry, including extensive international drug development and corporate development responsibilities. He was previously Chief Operations Officer and President of US Operations, as well as a member of the Board, at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focused on respiratory diseases. Subsequent to joining Vectura in 2010, Trevor played an integral leadership role in the company's successful development, including the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016. \n \nPrior to joining Vectura, Trevor held the roles of Chief Executive Officer and Chief Operating Officer at Critical Therapeutics, Inc. (now Chiesi USA, Inc.), a US listed specialty pharmaceutical company. He has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.), Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc). Trevor trained as a microbiologist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986. He was awarded an MBA from Henley Management College in 1997.\n \nJaime Ellertson, Non-Executive Chairman, commented:\n \n\"I would like to welcome Dr Trevor Phillips to hVIVO. Trevor brings extensive respiratory drug development and commercialisation experience to hVIVO, which will play a vital role in guiding our partnering and collaboration strategies in respiratory and infectious diseases. We believe Trevor will strengthen the Board as we progress our precision medicine based inventions and products forward towards commercialisation.\"\nDr Trevor Phillips, aged 56, is a director/partner or has been a director/partner of the following companies/partnerships during the previous five years:\nCurrent\n\n\n\n\nProstratex Limited\n\n\n\n\nPrevious\n\n\n\n\nAndar...